leadf
logo-loader
viewPolarean Imaging PLC

Polarean Imaging expects top-line clinical trial data by year-end

"We have now entered a crucial period for the company as the clinical trials near completion"

Polarean Imaging PLC -

Polarean Imaging PLC (LON:POLX) expects top-line data for its two clinical trials to be available by the year-end.

"We have now entered a crucial period for the company as the clinical trials near completion," said Richard Hullihen, chief executive.

Enrolment in the lung transplant pathway trial is now at 98% while 87% of the lung lobe trial has now been filled.

Polarean’s technology enhances images produced by MRI scans in patients suffering from lung conditions.

Currently, MRIs don’t help much in lung analysis but Polarean’s drug-device combination uses hyperpolarised 129-Xenon gas to generate 3D pictures.

By inhaling and holding a small amount of the gas in the lungs for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.

There are now 25 of its hyperpolarised Xenon systems.

Investment in the trials meant losses in the half-year to June were US$3.4mln. In July, the company raised US$2.1mln in a placing.

Quick facts: Polarean Imaging PLC

Price: 39.98 GBX

AIM:POLX
Market: AIM
Market Cap: £64.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...

on 19/6/20

2 min read